<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01338441</url>
  </required_header>
  <id_info>
    <org_study_id>2010-022000-41</org_study_id>
    <nct_id>NCT01338441</nct_id>
  </id_info>
  <brief_title>Selections of Subjects With Important Changes in Their Cardiac Repolarization Parameters for the Procurement of Skin and Blood Samples</brief_title>
  <acronym>iQTEST</acronym>
  <official_title>Selections of Subjects With Dramatic Changes in Their Cardiac Repolarization Parameters After a Pharmacologic Stimulus Aiming to Collect Their Skin Biopsy and Blood Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ectycell SASU</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre and Marie Curie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ectycell SASU</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study main objective is to assess the changes in the ventricular repolarization (measure
      by the delta QTcf) after drug induced stimulation, compare to placebo, in order to identify
      subjects with extreme responses and collecting their skin and blood samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An ECG is performed after a dose of sotalol on about 100 healthy subjects in order to
      identify about 20 extreme responders (10 high responders and 10 non responders) assessed as
      Delta QTcf compare to baseline. The ECG will be measured and the delta QTcf will be
      calculated on the 20 selected subjects in a second part of the clinical trial, cross over
      erythromycin/placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolongation of cardiac QT due to erythromycin compare to Placebo reported as Delta QTcf</measure>
    <time_frame>1hour and 20 minutes</time_frame>
    <description>Delta QTcf is measured at H0, H0+20 minutes, and H0+1h20, on groups' erythromycin and placebo. QTcf may be adjusted based on the pharmacokinetic data to ensure time of the plasmatic pick is used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison Delta QTcf eryhtromycin-sotalol</measure>
    <time_frame>over 3 hours</time_frame>
    <description>compare the effect of erythromycin and sotalol on QT prologation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of erythromycin Twave morphologie changes</measure>
    <time_frame>1hour and 20 min</time_frame>
    <description>Analysis of Qwave morphologic changes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Cardiology: RR / QT</condition>
  <arm_group>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <description>4mg/Kg, IV during 20 min once</description>
    <arm_group_label>Erythromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4mg/Kg, IV during 20 min once</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 40 years of age

          -  Caucasian origin

          -  BMI 19 to 29 kg/m²

          -  Informed Consent obtained

          -  National Health Security Number

          -  Eligible for Phase I as mentioned in the national registry of healthy volunteers

          -  For woman: use of an effective contraceptive method

        Non Inclusion Criteria:

          -  Asthma

          -  Heart Rate &lt; 50 bpm

          -  Hypotension with systolic blood pressure&lt; 100 mm Hg.

          -  atrioventricular block (PR interval &gt; 200 ms)

          -  Known Chronic illness (hepatic, renal or cardiac impairment, etc..)

          -  Raynaud's phenomenon

          -  Drug known to prolong QT
             (http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm) in the last 7 days.

          -  All chronic treatments are forbidden exceptive : oral contraceptives, paracetamol,
             vitamins and comfort treatment that do not prolong the QT

          -  Known family or individual past history of QT prolongation or unexplained syncope

          -  (QTcF) &gt; 450 ms

          -  QRS interval non assessable on ECG at rest or bundle-branch block, QRS &gt; 100 ms

          -  Allergy to macrolide type antibiotics

          -  Known allergy to sotalol or lidocaine

          -  Positive blood pregnancy test (Inclusion visit)

          -  Known abnormal haemostasis

          -  Kaliemia&lt; 3.5 mmol/L

          -  Magnesemia&lt; 0,7 mmol/L

          -  Under exclusion period or participating to another clinical trial on a new medicinal
             product

          -  Creatinin clearance &lt; 80 ml/min (Cockroft and Gault formula)

          -  AST-ALT &gt;3x upper normal limit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Sebastien Hulot, MD</last_name>
    <role>Study Director</role>
    <affiliation>University PMCurrie-INSERM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BIOTRIAL</name>
      <address>
        <city>Rueil Malmaison</city>
        <zip>92500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>September 14, 2011</last_update_submitted>
  <last_update_submitted_qc>September 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug induced QT prolongation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

